Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.

ABSTRACT:

Background

Since 2015, the European pulmonary hypertension guidelines recommend the use of combination therapy in most patients with pulmonary arterial hypertension (PAH). However, it is unclear to what extent this treatment strategy is adopted in clinical practice and if it is associated with improved long-term survival.

Methods

We analysed data from COMPERA, a large European pulmonary hypertension registry, to assess temporal trends in the use of combination therapy and survival of patients with newly diagnosed PAH between 2010 and 2019. For survival analyses, we looked at annualised data and at cumulated data comparing the periods 2010-2014 and 2015-2019.

Results

A total of 2531 patients were included. The use of early combination therapy (within 3 months after dia

SUBMITTER: Hoeper MM 

PROVIDER: S-EPMC9160392 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature